Connect with us

Technology

Frost & Sullivan Released Report: “BiBo Pharma: A Global CDMO Leading in Advanced Biopharmaceutical Manufacturing Technologies”

Published

3 months ago

on

SHANGHAI, Sept. 2, 2024 /PRNewswire/ — Frost & Sullivan released a report, titled “BiBo Pharma: A Global CDMO Leading in Advanced Biopharmaceutical Manufacturing Technologies”. The report explores a global CDMO leading the “The Fourth Revolutionary Wave of Biologics Manufacturing” and pioneering the next generation of CDMO models.

The global biomanufacturing capacity gap and budget constraints have ignited the “The Fourth Revolutionary Wave of Biologics Manufacturing”, with production sites expanding towards million-liter scales. In this context, Contract Development and Manufacturing Organizations (CDMOs) have become key players in global biomanufacturing. In 2023, BiBo Pharma, founded in Boston, USA, introduced a new generation of ultra-large production platforms, marking a new era in biomanufacturing. BiBo Pharma is breaking capacity barriers and reducing antibody drug production costs from the international average of hundreds of dollars to just $10 per gram, offering disruptive solutions to global biopharmaceutical companies.

Part I: BiBo Pharma 1.0 : Reflecting on the Past – Originating in Boston, USA, and Navigating through the Global CDMO development Journey

In the increasingly competitive CDMO industry, BiBo Pharma continues to advance. This success is due not only to their precise grasp of market opportunities but also to their breakthroughs in core biopharmaceutical industrialization technologies. Sailing from Boston, BiBo Pharma has been committed to the commercial production of biologics since its inception. The company independently designed and manufactured the ultra-large stainless steel bioreactors and pioneers a new generation of production models. In 2023, BiBo Pharma successfully completed the construction of a 30,000L single-tank ultra-large-production line, and in March 2024, it successfully commenced operations.

BiBo Pharma developed a comprehensive technology platform for microbial fermentation, mammalian cell culture, gene therapy, and antibody-drug conjugates (ADC). This platform offers one-stop services from DNA to IND/BLA and large-scale commercial production. To date, BiBo Pharma has offered CDMO services for more than 130 large molecule projects. Their operations adhere to international quality and management standards, solidifying BiBo Pharma’s position on the global CDMO stage after a decade of dedicated effort, and pioneering the next generation of CDMO models.

Part II: BiBo Pharma 2.0: Current Focus – Upgrading Strategies and Expanding Capabilities

//30,000L Capacity Advantage and Global First Delivery Advantage as an Industry Pioneer//

Major global CDMOs are expanding their large-scale commercial production capacities by focusing on the construction of large-scale stainless steel bioreactors. The future direction involves advancing from the current 15,000L reactors to fourth-generation ultra-large-scale production technologies.

BiBo Pharma is the first and only CDMO to deliver a new generation of ultra-large stainless steel bioreactors with a maximum working volume of 30,000L per tank. This is an engineering scale-up of over 2.5 times compared to the current 15,000L (total volume) standard in large-scale biopharmaceutical production. BiBo Pharma leverages economies of scale and cost-sharing to offer a potential solution to reduce costs on the basis of ensuring independently designed core equipment and a controllable supply chain.

PanFlex®-Engineering: Breaking Through the “Quality-Cost-Efficiency” Triangle  

The conventional factory construction process adopts an engineering design model that proceeds from the top level down to the lower levels. PanFlex®-Engineering employs a “Process is King” strategy, using standardized units to reverse-engineer a complete factory. As a result, PanFlex®-Engineering system transcends the impossible triangle of “quality-cost-efficiency.” Remarkably, it took less than 18 months to deliver a 30,000L ultra-large production platform, roughly half the time and cost of similar projects worldwide. In addition, the 30,000L platform passed quality audits from the U.S., EU, and Chinese clients. Leveraging its PanFlex®-Operation system, Bibo Pharma achieved a “Right on First Time” in March 2024 when the platform was put into operation with a 100% success rate in subsequent production.

Grand-CHO Platform: A “Three-in-one” Approach to Innovation

A “Three-in-One” approach to innovation——Grand-CHO Platform involves advances in cell line development, process research, and production technology for ultra-large-scale platforms.

Grand-CHO platform improves cell line expression and stability, optimizes commercial production processes of different scales, and offers other benefits. The second-generation Epic-CHO cell line achieves a high expression level of 10 g/L at the mini-pool stage and offers more than double the stability of leading international cell lines, laying a solid foundation for large-scale production.

Grand-CHO technology enables high-density and large-scale cell storage, while seamlessly integrating a 3,000L N-1 perfusion process and a 30,000L intensified Fed-batch production process. Compared to traditional methods, Grand-CHO technology reduces production cycle time by 30%, doubles the yield per fermentation volume, and cuts restart time for 30,000L projects from 60 days to 30 days. Grand-CHO technology, integrated with the 30,000L ultra-large-scale production line, is fundamentally transforming the overall production efficiency of biopharmaceuticals.  

Pulse Continuous Manufacturing (PCM)

The combination of BiBo Pharma’s PanFlex®-Engineering and Grand-CHO technology has led to a groundbreaking production model — Pulse Continuous Manufacturing (PCM). PCM releases a single high-volume batch upstream, such as 60,000 liters per pulse (60kL/P). It then processes multiple downstream batches continuously based on each unit’s operation time. PCM significantly improves production efficiency, boosting overall line efficiency by 50% to 300%. PCM’s success is driven by the interconnected equipment enabled by PanFlex®-Engineering. Additionally, BiBo’s P03 plant has implemented an automated process control system (PAS) that enables full digital integration across the facility, making the execution of the PCM model more efficient and seamless. 

Technology Integration Drives Reduction of Antibody Drug Production Cost to $10 per Gram

The primary initiative to solve the constraints of production costs, is the international breakthrough of the first-ever 30,000L single-tank ultra-large-scale production line. Integrating PanFlex®-Engineering, Grand-CHO technology, and a pulse continuous production mode, BiBo Pharma reduce antibody drug production cost from hundreds of dollars to $10 per gram.

An Engineering and Technical Service Provider

BiBo Pharma has launched the pioneering “Blue Whale Program,” a financial risk-free manufacturing solution powered by the PanFlex® system. This program offers tailored production line construction services to global clients, which reduces the construction costs and timelines by 50%. This allows clients to postpone capital expenditure decisions from Phase I/II to Phase III of clinical trials, giving them more time to make informed investment choices. Additionally, the program provides a risk reduction feature: fees paid by clients are refundable regardless of whether the product succeeds in the market. This effectively offers additional insurance for commercialization and mitigates risks in the R&D and production phases.

Part III: BiBo Pharma 3.0: Shaping the Future – Establishing Comprehensive Technology Industry Advantages and Leading the Next Chapter

BiBo Pharma establishes an intensive production model, which underpins the company a diversified, full-technology platform offering one-stop CDMO services. With its Boston R&D center and global production capabilities, BiBo Pharma delivers high-quality services adhering to international standards. BiBo Pharma utilizes its unparalleled industry advantages to empower the global biopharmaceutical companies by reshaping the cost structure of biologics.

Additionally, the “Blue Whale Program” expands BiBo Pharma’s established engineering solutions, reaching more clients with commercial production needs. Frost & Sullivan expects that these capabilities and advantages will position BiBo Pharma as the best solution for global pharmaceutical companies in the future.

To read the full content, go here: https://www.frost.com/news/press-releases/bibo-pharma-a-global-cdmo-leading-in-advanced-biopharmaceutical-manufacturing-technologies/

Media Contact
Contact: Qian Li
Company Name: Frost & Sullivan
Website: http://www.frostchina.com
Email: qian.li@frostchina.com 

View original content:https://www.prnewswire.com/apac/news-releases/frost–sullivan-released-report-bibo-pharma-a-global-cdmo-leading-in-advanced-biopharmaceutical-manufacturing-technologies-302235863.html

SOURCE Frost & Sullivan

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

CGI convenes telecom leaders to redefine industry transformation

Published

53 minutes ago

on

November 25, 2024

By

Roundtable explores the potential of Telecommunications in the hyper agile world and Global Capability Centers changing the landscape

BANGALORE, India, Nov. 25, 2024 /PRNewswire/ — CGI (TSX: GIB.A) (NYSE: GIB), one of the largest independent IT and business consulting services firms in the world, recently hosted Telco Next, the first of its kind industry roundtable, where CGI leaders were joined by industry and technology experts to explore the future of telecommunications and media for enterprises as well as Global Capability Centers (GCCs).

Telco Next highlighted the significant need for a shift in the telecommunications industry and seeding a more collaborative approach between telcos, System Integrators (SIs), hyperscalers, and technology providers. The discussion spotlighted how system integrators turbocharge time-to-market by harnessing their deep expertise in verticals, technology domains, and innovation. It also underscored the transformative shift from transactional supplier dynamics to strategic partnerships that prioritize tangible, outcome-driven success.

Rakesh Aerath, President, CGI Asia Pacific Global Delivery Center of Excellence, speaking at the event said, “At CGI, we recognize the importance of driving value for our partners, vendors, clients, and GCCs by fostering collaboration, innovation, and thought leadership. Hosting Telco Next is a strategic step in bringing together industry leaders and creating an ecosystem that will enable telcos to overcome challenges and geographical boundaries and embrace innovation.”

The event also fostered conversations around communication trends, emerging growth opportunities, digital platforms for new services, and offered insights on addressing industry challenge of transforming from telcos to tech organizations. It featured an insightful keynote, engaging panel discussions from industry veterans, and roundtable sessions focused on digital transformation, the role of GCCs as innovation hubs, and strategies for building value within GCCs. As GCCs expand, CGI leverages its experience in supporting existing GCCs in India to help clients establish new centers and establish partnerships with emerging GCCs

Arun Karna, Managing Director & CEO of AT&T Global Network Services India remarked, “It’s very invigorating and energizing to be at the CGI Telco Next event. It’s a great chance to meet up with peers and leaders and hear their perspectives. And, I would say there is a lot of talk about partnerships and ecosystems, which is so heartening to hear.”

About CGI

Founded in 1976, CGI is among the largest independent IT and business consulting services firms in the world. With 90,250 consultants and professionals across the globe, CGI delivers an end-to-end portfolio of capabilities, from strategic IT and business consulting to systems integration, managed IT and business process services and intellectual property solutions. CGI works with clients through a local relationship model complemented by a global delivery network that helps clients digitally transform their organizations and accelerate results. CGI Fiscal 2024 reported revenue is $14.68 billion CA and CGI shares are listed on the TSX (GIB.A) and the NYSE (GIB). Learn more at cgi.com.

cgi.com/newsroom

Photo – https://mma.prnewswire.com/media/2566140/CGI_Telco_Next.jpg

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/cgi-convenes-telecom-leaders-to-redefine-industry-transformation-302314823.html

Continue Reading

Technology

AU Small Finance Bank’s New AU SPONT Credit Card: 5 Reasons It is Perfect for Daily Transactions

Published

53 minutes ago

on

November 25, 2024

By

AHMEDABAD, India, Nov. 25, 2024 /PRNewswire/ — 

5 Key Features and Benefits

The AU SPONT Credit Card is a RuPay credit card offering extensive rewards and convenience to meet all of one’s spending needs. Enjoy endless cashbacks, coin rewards on purchases, lounge access, card protection, contactless payments, and flexible EMI options. Additional cards are available for family members. Every transaction becomes rewarding with the freedom to spend and save. The card transforms everyday purchases into significant savings and benefits.

With cashbacks, rewards points, lounge access, payment protection, digital payments, loan options, and extra cards, the AU SPONT Credit Card makes spending more convenient and rewarding for the entire family.

5 Reasons It’s Perfect for everyday transactions:

Earn Coins on UPIWelcome Bonus: Get 500 coins for making the first UPI transaction via the AU 0101 appEarning: Get 5 coins on every UPI transaction done through AU 0101 appValidity: Coins earned never expireRedemption: Redeem coins for rewards in the AU Rewardz catalogue1% Cashback on TransactionsRate: 1% cashback on all spends, including UPI, online, POS, contactlessCash Back: Up to Rs.500 cashback per monthExclusions: Fuel, EMI, rent, government fees, education, insurance, cash withdrawalsComplimentary Lounge AccessAirports: 2 free visits per quarter to Domestic Airport lounges on Rs.30,000 quarterly spendsRailways: 2 free lounge visits per quarter for primary & add-on cardholdersOther Key BenefitsFuel Surcharge Waiver: 1% waiver up to Rs.100 per month on fuel spends between Rs.400-5,000Fraud Protection: Zero liability against fraudulent transactions, loss of card, phishing, counterfeit & skimming if reported

What Sets AU SPONT Credit Cards Apart?

The AU SPONT Credit Card stands tall for its immense value across all aspects of payment and usage. With generous, unrestricted cashbacks, an exclusive coin-based rewards system, complimentary domestic and railway lounge visits, fuel surcharge waivers, comprehensive fraud protection, and convenient digital payment options, the card redefines the entire payment experience. Users can enjoy superior savings, privileges, seamless transactions, complete security and assistance whenever required. For spending that transcends into memorable rewards at every swipe or tap, the AU SPONT Credit Card remains unmatched in what it delivers, positioning it as a frontrunner.

About AU Small Finance Bank

AU Small Finance Bank, one of India’s leading small finance banks, is committed to transforming banking by focusing on customer-centric services and a deep understanding of the Indian market. More details on AU Small Finance Bank and its financial products like credit cards can be found online.

Logo: https://mma.prnewswire.com/media/2556252/AU_Small_Finance_Bank_Logo.jpg

 

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/au-small-finance-banks-new-au-spont-credit-card-5-reasons-it-is-perfect-for-daily-transactions-302311716.html

Continue Reading

Technology

Veeva Announces AI in Vault CRM

Published

3 hours ago

on

November 25, 2024

By

CRM Bot and Voice Control deliver GenAI-powered assistance in Vault CRM

SINGAPORE, Nov. 25, 2024 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced Vault CRM Bot and Vault CRM Voice Control, two new GenAI capabilities in Vault CRM. Unveiled at Veeva Commercial Summit Europe, CRM Bot and Voice Control join a host of new innovations coming to Vault CRM next year. With these new capabilities, companies can deploy AI that will have immediate value by boosting field productivity.

CRM Bot embeds the large language model (LLM) of your choice into Vault CRM to enable a wide range of context-driven tasks including pre-call planning, suggested actions, recommended content, and context-specific learning. Planned for availability in late 2025, CRM Bot is included in Vault CRM for no additional charge and requires the Vault Direct Data API.

AI-powered Voice Control brings the human voice as a user interface into Vault CRM by leveraging Apple Intelligence for hands-free operation of CRM via spoken commands. Planned for availability in late 2025, Voice Control is included in Vault CRM for no additional charge and requires Apple Intelligence and compatible devices.

Delivering AI within its products – like CRM Bot and Voice Control – is part of Veeva’s overall strategy to help enable AI for the life sciences industry. Veeva also provides the Vault Direct Data API for high-speed access to data needed for AI and the Veeva AI Partner Program that enables customers and partners to more easily build AI applications that integrate seamlessly with Vault applications.

“Vault CRM Bot and Vault CRM Voice Control bring the latest advances in generative AI into Vault CRM for more effective, productive reps,” said Arno Sosna, general manager of CRM products at Veeva. “Our product focus is to leverage AI for clear use cases with high impact and ensure smoother more effective deployments of advanced technologies.”

Veeva customers and life sciences industry professionals can learn about these innovations and more in the Vault CRM Product Roadmap session replay in Veeva Connect starting November 25.

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/veeva-announces-ai-in-vault-crm-302315002.html

SOURCE Veeva Systems

Continue Reading

Trending